Maintained anxiolytic effects of cannabidiol after treatment discontinuation in healthcare workers during the COVID-19 pandemic

Autor(es):Mostrar menos -

Souza, Jose Diogo S. ; Zuardi, Antonio W. ; Guimaraes, Francisco S. ; Osorio, Flavia de Lima ; Loureiro, Sonia Regina ; Campos, Alline Cristina ; Hallak, Jaime E. C. ; Dos Santos, Rafael G. ; Machado Silveira, Isabella Lara ; Pereira-Lima, Karina ; Pacheco, Julia Cozar ; Ushirohira, Juliana Mayumi ; Ferreira, Rafael Rinaldi ; Costa, Karla Cristinne Mancini ; Scomparin, Davi Silveira ; Scarante, Franciele Franco ; Pires-Dos-Santos, Isabela ; Mechoulam, Raphael ; Kapczinski, Flavio ; Fonseca, Benedito A. L. ; Esposito, Danillo L. A. ; Andraus, Maristela Haddad ; Crippa, Jose Alexandre S.

• Tipo de documento: Artigo Científico
• Fonte: FRONTIERS IN PHARMACOLOGY; v. 13, p. 9-pg., 2022-10-03.

Resumo

Objective: To assess whether the effects of oral administration of 300 mg of Cannabidiol (CBD) for 28 days on mental health are maintained for a period after the medication discontinuation. Methods: This is a 3-month follow-up observational and clinical trial study. The data were obtained from two studies performed simultaneously by the same team in the same period and region with Brazilian frontline healthcare workers during the COVID-19 pandemic. Scales to assess emotional symptoms were applied weekly, in the first month, and at weeks eight and 12. Results: The primary outcome was that, compared to the control group, a significant reduction in General Anxiety Disorder-7 Questionnaire (GAD-7) from baseline values was observed in the CBD group on weeks two, four, and eight (Within-Subjects Contrasts, time-group interactions: F1-125 = 7.67; p = 0.006; eta(p) (2) = 0.06; F1-125 = 6.58; p = 0.01; eta(p) (2) = 0.05; F1-125 = 4.28; p = 0.04; eta(p) (2) = 0.03, respectively) after the end of the treatment. Conclusions: The anxiolytic effects of CBD in frontline health care professionals during the COVID-19 pandemic were maintained up to 1 month after the treatment discontinuation, suggesting a persistent decrease in anxiety in this group in the real world. Future double-blind placebo-controlled clinical trials are needed to confirm the present findings and weigh the benefits of CBD therapy against potential undesired or adverse effects. (AU)

• Processo FAPESP: 08/09009-2 - Uso crônico de crack: densidade de transportador de dopamina, fatores genéticos e funcionamento executivo
• Beneficiário: Acioly Luiz Tavares de Lacerda
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 14/50891-1 - INCT 2014: Translacional em Medicina
• Beneficiário: Jaime Eduardo Cecilio Hallak
• Modalidade de apoio: Auxílio à Pesquisa - Temático
• Processo FAPESP: 20/12110-9 - Canabidiol (CBD) em pacientes com sintomas leves a moderados do Coronavirus 2019: um ensaio clínico randomizado, duplo-cego, controlado por placebo
• Beneficiário: José Alexandre de Souza Crippa
• Modalidade de apoio: Auxílio à Pesquisa - Pesquisa em Políticas Públicas